Device Trial Radar · NCT02302365
Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion
Last checked: Nov 20, 2026Latest source record: Jul 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Apr 2014
Primary completion
Jul 2017
Study completion Jul 2017
Sponsor
- Lead sponsor
- Terumo BCTPublic (4543.T)
- Sponsor type
- Industry
- First posted
- Nov 27, 2014
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, retrospective data collection of routine clinical use with the Spectra Optia® apheresis system for white blood cell depletion.
Conditions
- Leukocytosis
Interventions
Spectra Optia® Apheresis SystemDevice
White Blood Cell Depletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Decrease in White Blood Cell Count in Patient Following Apheresis ProcedureTime frame: immediately after apheresis procedure: on average this will be within 15 minutes after the end of the procedure
- Collection Efficiency (CE) for WBC (or Percent of Processed WBCs) Achieved by Spectra Optia.Time frame: immediately after apheresis procedure: on average this will be within 15 minutes after the end of the procedure
- Adverse EventsTime frame: Participants were followed for the duration of the procedure and for up to 24 hours after the procedure.
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
UZ Gasthuisberg
Leuven, Belgium
Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Johann-Wolfgang-Goethe-University Hospital
Frankfurt am Main, Germany
Szent Istvan and Szent Laszlo Hospital of Budapest
Budapest, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.